DalCor Pharma U.K. Ltd. (London, U.K.) raised $100 million in a series B round with Sanderling Ventures, Andre Desmarais, Caisse de depot et placement du Quebec, the Fonds de solidarite FTQ, CTI Life Sciences and undisclosed investors. The company is developing dalcetrapib (formerly RG1658), a small molecule inhibitor of cholesteryl ester transfer protein (CETP) to treat cardiovascular disease.

DalCor in-licensed the molecule from Roche (SIX:ROG; OTCQX:RHHBY) last year. This month, DalCor plans to start a 5,000-patient Phase III study of dalcetrapib in a genetically defined subset of acute coronary syndrome patients.

Roche discontinued development of dalcetrapib in 2012 after it failed in a Phase III study to treat coronary heart disease (CHD). DalCor said retrospective analyses of the Roche study showed dalcetrapib had efficacy in the subset of patients DalCor is pursuing.DalCor also disclosed on Tuesday that it raised $50 million in a series A round last year.

Source: BioCentury